What is FluGen?
FluGen Inc. operates as a specialized biopharmaceutical entity focused on the development of the M2SR Vaccine Platform. Unlike traditional inactivated vaccines, the M2SR platform utilizes a live, single-replication influenza virus designed to elicit a comprehensive immune response. This mechanism is engineered to provide superior protection against both seasonal and drifted strains of the influenza virus, addressing the limitations of current standard-of-care immunizations. Beyond its primary focus on influenza, the company is strategically evaluating the versatility of the M2SR platform to combat other respiratory pathogens, including potential applications for COVID-19. By bridging the gap between academic research and commercial-scale biotechnology, FluGen maintains a pivotal role in the evolving landscape of infectious disease prevention.
How much funding has FluGen raised?
FluGen has raised a total of $20.4M across 5 funding rounds:
Debt
$3.2M
Other Financing Round
$9.4M
Series A
$2M
Debt
$5.5M
Debt
$234K
Debt (2014): $3.2M, investors not publicly disclosed
Other Financing Round (2015): $9.4M led by Knox Payments, Wisconsin Alumni Research Foundation, Venture Investors, and State of Wisconsin - Investment Board
Series A (2017): $2M supported by Knox Payments, Wisconsin Alumni Research Foundation, Venture Investors, and State of Wisconsin - Investment Board
Debt (2017): $5.5M, investors not publicly disclosed
Debt (2021): $234K backed by PPP
Key Investors in FluGen
Wisconsin Alumni Research Foundation
The Wisconsin Alumni Research Foundation is a nonprofit organization that manages intellectual property and technology transfer for the University of Wisconsin-Madison, supporting scientific innovation through strategic grants and asset management.
Venture Investors
Venture Investors Health Fund is a specialized VC firm that focuses on transformative healthcare solutions and university spinouts, leveraging deep connections to research institutions to drive medical breakthroughs.
State of Wisconsin - Investment Board
The State of Wisconsin Investment Board is a state-owned investment manager that oversees public retirement funds and trust assets, employing fundamental research to execute tactical asset allocations across diverse market sectors.
What's next for FluGen?
With the recent strategic investment, FluGen is poised to intensify its clinical development efforts and expand the utility of its M2SR platform. The company's roadmap likely involves scaling manufacturing capabilities and advancing multi-center clinical trials to validate the efficacy of its intranasal vaccine candidates. As the firm moves deeper into its lifecycle, the focus will shift toward regulatory milestones and potential commercialization partnerships. Given the ongoing global emphasis on respiratory health and pandemic preparedness, FluGen's ability to demonstrate broad-spectrum protection will be a key determinant in its long-term market valuation and impact on public health outcomes.
See full FluGen company page
